The expected yield for AGN is 2.07 %, this seems a healthy dividend return and if Allergan Plc is also cheaply priced, and has a low debt to equity ratio and if Allergan Plc makes a good profit.
AGN has a trailing price to earnings ratio (P/E) of -6.49. The ratio is determined by the performance in the last 12 months. The P/E is negative, Allergan Plc is losing money. The asset does not seem a good fit for long term dividend investing.
With the Debt To Equity rate of AGN (0.37) we can conclude that Allergan Plc does not seem to have more liabilities than equity provided by the shareholders. A lower D/E ratio stands for a less risky investment.
On average analists predict that AGN will be correctly priced after a 31%. change. We can expect some long term capital gains.
Latest news for AGN
2019-05-16 Notable Thursday Option Activity: AGN, DAL, AMGN
Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Allergan PLC Symbol AGN where a total volume of 9 658 contracts has been traded thus far today a contract volume which is representative of approximately 965 800
Original Article @ Nasdaq
2019-05-15 Appaloosa takes stakes in Alibaba, Amazon but drops big name banks
David Tepper's Appaloosa LP bulked up its positions in technology companies and dropped two big financial institutions from its portfolio at the end of March, according to a regulatory filing Wednesday. Appaloosa added a million shares of Alibaba Group Holding , 165,000 shares of Amazon.com Inc. and 200,000 shares of Salesforce.com Inc. . It bolstered holdings in Facebook Inc. , Micron Technology Inc. , and PG&E while more than doubling its stake in Allergan PLC to 3.13 million shares from 1.15 million at the end of December. Appaloosa has been pressuring the drug company to split its chief executive and chairman roles as part of its effort to push Allergan to review its business strategy. Meanwhile, the hedge fund sold out of Wells Fargo & Co. , Bank of America Corp. , and NRG Energy Inc. , according to its 13F filing. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Original Article @ MarketWatch
2019-05-15 Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
LONDON, May 15, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant's Board of Directors. Mr. Nelson served as President and Chief Executive Officer, and member of the Board of Directors, of MAP Pharmaceuticals, Inc. from 2005 until its acquisition by Allergan plc in 2013. Mr. Ludlum served as Chief Financial Officer of a molecular diagnostics company, CareDx, Inc., where he led its initial public offering in 2014. "We are truly honored to have Tim and Ken join our board of directors," said Todd Zavodnick, Chief Executive Officer of Dermavant. "Both Tim and Ken bring over 20 years of extensive leadership experience in the biotechnology, pharmaceutical, drug delivery, molecular diagnostics, and/or medical device industries. Their expertise in building successful companies will be a valuable resource to Dermavant as we initiate our Phase 3 program for tapinarof for the treatment of psoriasis this quarter." "Joining Dermavant at this important time in the company's development is a privilege," said Mr.
Original Article @ Benzinga
2019-05-10 Knee Injections Could Hold the Key to Fighting Aging
(Bloomberg Businessweek) -- To hear Nathanial “Ned” David tell it, the osteoarthritis drug his Unity Biotechnology began testing in human subjects last fall is about far more than just helping aging weekend warriors regrow cartilage in their damaged knees. It’s the first step toward making us all feel young again. “Aging is not a rigid, inflexible phenomenon,” he told a conference room full of Wall Street analysts and financiers in Midtown Manhattan. “Nature has created control knobs that it uses and turns to change the life span of different organisms. Finally, as scientists, we are learning how to identify some of these knobs and actually turn them as a therapeutic strategy.” David, 51, was in New York to explain the science behind UBX0101, the drug Unity has in late Phase I clinical trials to treat the intractable arthritic condition, which affects 14 million Americans. The company is expected to release early results within the next several weeks. Analysts, scientists, and patients are watching closely.
Original Article @ Bloomberg
2019-05-09 Evidence is mounting that psychedelic drugs can help treat diseases. Here are the most promising uses.
There's been a recent resurgence of interest in psychedelic drugs' potential to address conditions like anxiety and depression . That research is beginning to lead to the development of new and novel drugs . Illicit drugs like mushrooms , ecstasy (MDMA) , and ketamine are inspiring a range of potential treatments for diseases that currently lack good medications. Denver is set to become the first US city to decriminalize psychedelic mushrooms, after voters there approved a measure to direct police to make enforcing laws against them a low priority. Visit Business Insider's homepage for more stories. Once portrayed as illegal ways to "drop out" or "tune in," psychedelic and semi-psychedelic drugs like psilocybin and ecstasy are finally starting to turn into federally-regulated medicines. The tide began to turn over the summer, when a little-known startup backed by Silicon Valley tech mogul Peter Thiel churned out enough of the active ingredient in magic mushrooms to send 20,000 people on a psychedelic trip.
Original Article @ Business Insider
2019-05-09 Novartis to Buy Takeda Eye Drug Assets in $3.4 Billion Deal
The main product in the deal is Xiidra, prescription drops that compete with Allergan Plc’s blockbuster Restasis to relieve dry-eye disease, a common condition that can hinder daily activities ranging from reading to driving. Along with $3.4 billion in cash upfront, Novartis agreed to pay as much as
Original Article @ Yahoo Finance
2019-05-07 What You Need to Know About Allergan's Solid Q1 Performance
Here's why the drugmaker topped revenue and earnings expectations in Q1.
Original Article @ The Motley Fool